GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease (SHIELD-2)
A 52 Week Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Sponsor: GlaxoSmithKline
Terminated
This study was terminated due to the lack of efficacy of GSK1605786A in Crohn's disease based on the results of Study CCX114151.
Listed as NCT01316939, this PHASE3 trial focuses on Crohn's Disease and remains terminated or withdrawn. Sponsored by GlaxoSmithKline, it has been updated 13 times since 2011, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE3
▶ Show 8 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE3
-
Sep 2020 — Nov 2020 [monthly]
Terminated PHASE3
-
Jun 2018 — Sep 2020 [monthly]
Terminated PHASE3
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE3
-
Oct 2017 — May 2018 [monthly]
Terminated PHASE3
-
Aug 2017 — Oct 2017 [monthly]
Terminated PHASE3
-
Feb 2017 — Aug 2017 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
May 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aalborg, Denmark , Aarhus, Denmark , Abbotsford, Canada , Adelaide, Australia , Afula, Israel , Aichi, Japan , Amsterdam, Netherlands , Ankara, Turkey (Türkiye) , Ann Arbor, United States , Atlanta, United States and 204 more locations